- Total Pro Portfolios with BAX:
- American Beacon Lg Cap Value AMR AAGAX
- BlackRock Health Sciences Instl SHSSX
- Schwab Health Care SWHFX
- Longview Asset Management LLC
- Relational Investors LLC
- Renaissance Technologies
- Americap Advisors
- Delaware Dividend Income A (DDIAX)
- Fidelity Value (FDVLX)
- Healthcor Management
- show more
- 19
- Goldman Sachs Large Cap Value Inst GSLIX
- Franklin Global Health Care A FKGHX
- Rittenhouse Asset Management Inc
- Clovis Capital Management, LP
- Maverick Capital
- Argus Management
- Navellier & Associates
- The Claymore/Zacks Sector Rotation ETF (XRO)
- Delaware Large Cap Value (DELDX)
- Total Do-It-Yourself Portfolios with BAX:
- Ron's picks
- Bapu Secretary Portfolio 1
- Schwab: The A Team
- Maggi Portfolio 1
- Maizey
- Sportrider Portfolio 1
- shs 01-18-07
- tarn ananda Portfolio 1
- Irv Greenberg Portfolio 1
- henaoj Portfolio 1
- Ronnie Benjamin Portfolio 1
- sboat
- Gino Fanelli Portfolio 1
- paul7576 3
- Annrc Portfolio 1
- msawicki Portfolio 1
- lindafraser Portfolio 1
- lsc Portfolio 1
- 1 Portfolio 1
- johnlirvin Portfolio 1
- confusion Portfolio 1
- Morgan Stanley Model Portfolio
- Goal
- rlatuchie Portfolio 1
- artesiaca@yahoo.com Portfolio 1
- RRR111
- diverson Portfolio 1
- Steve Kendall Portfolio 1
- LaxshmiBW03
- Chris - Large Cap
- BENITRANS ST7-2
- chuckcollins Portfolio 1
- Albinon Portfolio 1
- mccamere Portfolio 1
- amrainc Portfolio 1
- swish44 Portfolio 1
- Blade's Portfolio
- jamminmo Portfolio 1
- faltany Portfolio 1
- D and B
- Cramer Defense Fund
- Cramer's Medical Defensive Portfolio
- bhubb2
- jddawn Portfolio 1
- my top holdings
- 2007 Buys
- Market Edge Test
- watch 0507
- swish
- mbroso Portfolio 1
- fRANKLIN bAXTER
- show more
- 209
- Ameritrade
- Jim Keegan Portfolio 1
- CURT HOVEY Portfolio 1
- cwcastle
- Sportrider US
- 2007 Stock Portfolio
- E1
- Aqua's Portfolio
- Kathi Sanger Portfolio 1
- Jim Vergas Portfolio 1
- George Cole
- As of Feb 20
- howie
- NuttnHunee Portfolio 1
- Fargus Portfolio 1
- cbabilo Portfolio 1
- craigc Portfolio 1
- wisniewskilaw Portfolio 1
- greatmess Portfolio 1
- happydrak Portfolio 1
- Gary Green Portfolio 2
- fweb1125 Portfolio 1
- Stephen Stewart Portfolio 1
- JTMedina
- Steve24 Portfolio 1
- equinet Portfolio 1
- jmwatl Portfolio 1
- Laxshmi91
- hogdoc Portfolio 1
- marcus
- Ronnie Benjamin Portfolio 2
- tappermd Portfolio 1
- SUPRATRADE VIRTUAL II
- mlapca Portfolio 1
- cmudd Portfolio 1
- RogerB
- houngab Portfolio 1
- LUTHER N. KNAUB Portfolio 1
- pjl1520 Portfolio 1
- freeagents7 Portfolio 1
- kwikram2
- VaBthang4's Defensive Portfolio
- Tom'T
- test999
- rwelshmcp Portfolio 1
- PhilWarren Portfolio 1
- niptron4 Portfolio 1
- Jefferino
- Scaramouche
- DHADICK Portfolio 1
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:barrons3 |
Date:05 21 09 |
So many of these are bordering on their 52-week lows from the bad old days. Others can't get out of their way even when the fundamentals are good: Baxter (BAX), Abbott (ABT), Bristol Myers (BMY). |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:04 29 09 |
On the vaccine side, companies like GlaxoSmithKline, Baxter(BAX) and Crucell(CRXL) stand to benefit, he said. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:02 28 09 |
With double-digit earnings growth, a robust balance sheet and strong R&D efforts under way, Baxter could see its shares climb by nearly 20%, to 65, by year's end. |
|
Not yet rated
Rate now:
|
|
Date:12 30 08 |
|
11 |
|
Not yet rated
Rate now:
|
|
Date:12 16 08 |
|
Healthcare |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:11 22 08 |
Baxter International (BAX), C.R. Bard (BCR), Teva Pharmaceutical (TEVA) and Express Scripts (ESRX) are four health-care stocks likely to outperform in the coming year, even if the global economy remains depressed. The company's geographic reach makes it less dependent on conditions in any one region. Baxter has "good earnings visibility, with little economic sensitivity," says Lai. "They have become less of a distributor of medical equipment like IV supplies, and more of an innovator." Behind that shift is Baxter's bioscience division, whose third-quarter revenue grew 23%, to $1.3 billion. Its products include plasma-based proteins used to treat hemophilia. Another promising area: recombinants, which are produced synthetically, not from human blood, and are used to treat immune disorders. Recombinant sales totaled $516 million in the quarter, versus $432 million a year before. "Between the therapies they have for hemophilia and immune-system-deficient patients, that's a very good market," says Willey. Baxter is also benefiting from a favorable shift in its product mix, as the fastest growth is coming from its more profitable products in biosciences. |
|
Not yet rated
Rate now:
|
|
Date:11 15 08 |
|
20% |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:11 15 08 |
Based in Deerfield, Ill., Baxter sweetened its quarterly 20%, to 26 cents a share from 21.75 cents, payable Jan. 6 to holders of record Dec. 10. The ex-date is Dec. 8. This is the third hike since February 2007, and gives the stock a 1.71% yield. Dividends have been ongoing since 1934. Baxter, which set a 52-week high of 71.53 on the Big board Aug. 15, was recently quoted at about 61 and is rated Buy. Third-quarter diluted earnings surged 21%, to 74 cents a share from 61 cents a year earlier. Sales rose 15%, to $3.2 billion. Commenting on the dividend boost, CEO Robert L. Parkinson Jr. said: "Because of the medically necessary nature of our product offerings, diversified business portfolio and extensive global presence, we have the financial strength and flexibility to provide enhanced value to shareholders and invest in future growth despite the uncertain macro environment." |
|
Not yet rated
Rate now:
|
|
By:pgerke |
Date:10 27 08 |
great company with near recession proof market |
|
Not yet rated
Rate now:
|
|
By:ctwilson57 |
Date:10 17 08 |
Competitor |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:carla dazzi |
Date:11 05 08 |
don't know where it's hitting next |
|
Not yet rated
Rate now:
|
|



